Profiel
Brian Hubbard currently works at Sprout Bioventures, as Partner from 2018.
Dr. Hubbard also formerly worked at Dogma Therapeutics, Inc., as Chief Executive officer from 2015 to 2020, Novartis AG, as Director from 2002 to 2008, The Broad Institute, Inc., as Director from 2011 to 2015, and Merck Global Health Innovation LLC, as Sr. Director from 2008 to 2011.
Dr. Hubbard received his undergraduate degree in 1994 from The College of William & Mary, doctorate degree from the University of Illinois, and graduate degree from Harvard Medical School.
Actieve functies van Brian Hubbard
| Bedrijven | Functie | Begin |
|---|---|---|
Sprout Bioventures
Sprout Bioventures Investment ManagersFinance Sprout Bioventures invests in companies located in the United States. The firm focuses on Biotechnology Research sectors. It participates in early stage transactions. | Private Equity Investor | 01-01-2018 |
Eerdere bekende functies van Brian Hubbard
| Bedrijven | Functie | Einde |
|---|---|---|
Dogma Therapeutics, Inc.
Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease | Algemeen Directeur | 02-08-2020 |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Directeur van Onderzoek - Eigen Vermogen | 02-08-2015 |
Merck Global Health Innovation LLC
Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health invests in companies located across the globe primarily in North America and Europe. The firm targets companies operating in the fields of drug discovery & clinical development, manufacturing, supply chain & IT, access to medicine & patient support and real world evidence generation It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million. | Directeur van Onderzoek - Eigen Vermogen | 02-09-2011 |
| NOVARTIS AG | Directeur van Onderzoek - Eigen Vermogen | 02-01-2008 |
Opleiding van Brian Hubbard
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
The College of William & Mary
The College of William & Mary Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois
University of Illinois Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Broad Institute, Inc.
The Broad Institute, Inc. BiotechnologyHealth Technology Engages in research and development in bio medicals to cure infectious disease, cancer, psychiatric research and cardiovascular diseases | Health Technology |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Global Health Innovation LLC
Merck Global Health Innovation LLC Investment ManagersFinance Merck Global Health invests in companies located across the globe primarily in North America and Europe. The firm targets companies operating in the fields of drug discovery & clinical development, manufacturing, supply chain & IT, access to medicine & patient support and real world evidence generation It provides financing for early and growth stage capital requirements with an investment size of USD 5 - 10 million. | Finance |
Sprout Bioventures
Sprout Bioventures Investment ManagersFinance Sprout Bioventures invests in companies located in the United States. The firm focuses on Biotechnology Research sectors. It participates in early stage transactions. | Finance |
Dogma Therapeutics, Inc.
Dogma Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease | Health Technology |
















